A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics.

ASIA unversity > 資訊學院 > 生物資訊與醫學工程學系 > 期刊論文 > Item 310904400/102110

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/102110

Title:	A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics.
Authors:	張玲菊;LC, Chang;余永倫;MT, Hsieh;MT, Hsieh;SH, Wang;SH, Wang;鄒瑞煌;黃偉謙;Huang, Wei-Chien;HY, Lin;HY, Lin;HY, Hung;HY, Hung;LJ, Huang;LJ, Huang;SC, Kuo;SC, Kuo;*
Contributors:	生物科技學系
Date:	2016-03
Issue Date:	2017-03-01 05:55:30 (UTC+0)
Abstract:	We investigated the anticancer potential of a new synthetic compound, 7-(3-fluorophenyl)-4-methylpyrido-[2,3-d]pyrimidin-5(8H)-one (MT3-037). We found that MT3-037 effectively decreased the cancer cell viability by inducing apoptosis. MT3-037 treatments led to cell cycle arrest at M phase, with a marked increase in both expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1) as well as in CDK1 kinase activity. Key proteins that regulate mitotic spindle dynamics, including survivin, Aurora A/B kinases, and polo-like kinase 1 (PLK1), were activated in MT3-037-treated cells. MT3-037-induced apoptosis was accompanied by activation of a pro-apoptotic factor, FADD, and the inactivation of apoptosis inhibitors, Bcl-2 and Bcl-xL, resulting in the cleavage/activation of caspases. The activation of c-Jun N-terminal kinase (JNK) was associated with MT3-037-induced CDK1 and Aurora A/B activation and apoptosis. Immunofluorescence staining of tubulin indicated that MT3-037 altered tubulin networks in cancer cells. Moreover, an in vitro tubulin polymerization assay revealed that MT3-037 inhibited the tubulin polymerization by direct binding to tubulin. Molecular docking studies and binding site completion assays revealed that MT3-037 binds to the colchicine-binding site. Furthermore, MT3-037 significantly inhibited the tumor growth in both MDAMB-468 and Erlotinib-resistant MDA-MB-468 xenograft mouse models. In addition, MT3-037 inhibited the angiogenesis and disrupted the tube formation by human endothelial cells. Our study demonstrates that MT3-037 is a potential tubulin-disrupting agent for antitumor therapy.
Relation:	American Journal of Cancer Research
Appears in Collections:	[生物資訊與醫學工程學系 ] 期刊論文

Files in This Item:

File	Size	Format
index.html	0Kb	HTML	457	View/Open

Loading...